Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer.

@article{Monk2012TrabectedinAA,
  title={Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer.},
  author={Bradley J. Monk and H. Dalton and Ivor Benjamin and Adnan Tanovi{\'c}},
  journal={Current pharmaceutical design},
  year={2012},
  volume={18 25},
  pages={
          3754-69
        }
}
Trabectedin (ET-743, Yondelis®) is a novel marine antineoplastic alkaloid with a unique mechanism of action. The active substance trabectedin, a tetrahydroisoquinoline alkaloid, is a natural product originally isolated from the Caribbean sea squirt, Ecteinascidia turbinata and is currently manufactured by total synthesis. Trabectedin is licensed by the Spanish pharmaceutical drug company, PharmaMar and co-developed by Johnson & Johnson Pharmaceutical Research and Development, L.L.C., pursuant… CONTINUE READING
Highly Cited
This paper has 19 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

Similar Papers

Loading similar papers…